

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ryuichi Morishita & Munehisa Shimamura

Application No. 10/517,154**Filed:** July 11, 2005**Confirmation No.** 2664**For:** AGENTS FOR GENE THERAPY OF
CEREBROVASCULAR DISORDERS**Examiner:** Marcia Stephens Noble**Art Unit:** 1632**Attorney Reference No.** 6235-69895-01**FILED VIA EFS
ON NOVEMBER 12, 2007**SUBMITTED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(d)**

Listed on the accompanying form PTO-1449 and submitted herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent. This Information Disclosure Statement ("IDS") is being filed after the date of either a final action or, a notice of allowance, and before payment of the issue fee.

Submitted herewith is payment of \$180.00 to cover the fee as required by 37 C.F.R. § 1.97(d) and as set forth in 37 C.F.R. § 1.17(p).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By



Sheree Lynn Rybak, Ph.D.
Registration No. 47,913